Research Update: Positive Leukaemia Model Study

(AIM: SAR)   7 February 2011


                              SAREUM HOLDINGS PLC
                          ("Sareum" or the "Company")

                Research Update: Positive Leukaemia Model Study
Sareum  (AIM: SAR), the specialist cancer drug discovery business, is pleased to
announce  positive results from  its pre-clinical in-vivo  efficacy studies into
acute myeloid leukaemia (AML), the most common form of adult leukaemia.

A  recent  study  for  Sareum's  Aurora+FLT3  Kinase  programme  showed that the
leukaemia  regressed to such an extent that  no detectable cancer could be found
in  any  of  the  cases  treated  (ten  in  total)  with  a  Sareum compound. By
comparison,  leukaemia  increased  five  to  fifteen  fold in the study examples
treated  without  Sareum's  compound.   At  six  weeks  following  treatment, no
detectable  cancer could  be found  in two  of the  ten examples  dosed with the
Sareum compound. In the remaining eight treated examples, the average time taken
for the leukaemia to increase 5-fold was six weeks, compared to two weeks in the
untreated cases.

Sareum's CEO, Dr Tim Mitchell, commented: "The results of Sareum's study compare
very  favourably  with  those  from  similar  pre-clinical studies published for
Aurora  kinase inhibitors currently undergoing  clinical trials. We look forward
to  presenting  the  data  to  potential  licencees.  350,000 people  a year are
diagnosed  with leukaemia  and we  are very  pleased to  be contributing  to the
search for a cure for this disease".

 Sareum Holdings plc

 Tim Mitchell                 01223 497 700



 Merchant Securities Limited (Nomad)

 Simon Clements/Bidhi Bhoma   020 7628 2200



 Hybridan LLP (Broker)

 Claire Noyce                 020 7947 4350


Notes for editors:

About Sareum Holdings plc
Sareum  is  a  drug  discovery  company,  headquartered in Cambridge UK, that is
focused  on  producing  targeted  small  molecule  therapeutics to address unmet
medical  needs, primarily  in cancer.  Sareum aims  to successfully deliver drug
candidates  for licensing to  pharmaceutical and biotechnology  companies at the
pre-clinical or early clinical trials stage.

Sareum's Chk1 kinase cancer research programme is a joint research collaboration
with  The Institute of  Cancer Research and  Cancer Research Technology Limited.
Novel  chemical  compounds  developed  by  the  collaboration have been shown to
increase  the  effectiveness  of  current  cancer therapeutics in in-vivo cancer
models.

SKIL®  (Sareum Kinase Inhibitor  Library) is Sareum's  drug discovery technology
platform  that has so far produced  the Company's Aurora+FLT3, Aurora+ALK VEGFR-
3, FLT3  & TYK2 kinase cancer and  auto-immune disease research programmes. SKIL
can also generate drug research programmes against other kinase targets.

Sareum  Holdings  plc  joined  the  AIM  market  of the London Stock Exchange in
October  2004, trading under  the symbol  SAR.  For  further information, please
visit www.sareum.co.uk







This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: SAREUM HOLDINGS PLC via Thomson Reuters ONE

[HUG#1485695]